These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 27666138)

  • 1. D2-resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy.
    Peng J; Wei Y; Zhou F; Dai J; Zhong Y; Xie C; Qin Y; Gong J; Xiong B; Zhou Y
    Cancer Med; 2016 Oct; 5(10):2773-2780. PubMed ID: 27666138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection.
    Wang X; Shen Y; Zhu H; Zhao Y; Li Z; Qiu M; Li Q; Gou H; Yang Y; Cao D; Liu J; Yi C; Liao Z; Luo D; Bi F; Xu F
    Gastric Cancer; 2016 Jan; 19(1):245-54. PubMed ID: 25609451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
    Lee SJ; Sohn TS; Lee J; Park SH; Park JO; Lim DH; Park YS; Lim HY; Choi MG; Lee JH; Bae JM; Kim S; Kang WK
    Anticancer Res; 2014 Nov; 34(11):6585-91. PubMed ID: 25368262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients?
    Kilic L; Ordu C; Ekenel M; Yildiz I; Keskin S; Sen F; Gural Z; Asoglu O; Kizir A; Aykan F
    Med Oncol; 2013; 30(3):660. PubMed ID: 23877872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.
    Park SH; Sohn TS; Lee J; Lim DH; Hong ME; Kim KM; Sohn I; Jung SH; Choi MG; Lee JH; Bae JM; Kim S; Kim ST; Park JO; Park YS; Lim HY; Kang WK
    J Clin Oncol; 2015 Oct; 33(28):3130-6. PubMed ID: 25559811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rate.
    Feng YR; Jin J; Ren H; Wang X; Wang SL; Wang WH; Song YW; Liu YP; Tang Y; Li N; Liu XF; Fang H; Yu ZH; Li YX
    BMC Cancer; 2017 Mar; 17(1):182. PubMed ID: 28279170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
    Hwang JE; Kim H; Shim HJ; Bae WK; Hwang EC; Jeong O; Ryu SY; Park YK; Cho SH; Chung IJ
    J Cancer Res Clin Oncol; 2019 Aug; 145(8):2157-2166. PubMed ID: 31273512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemoradiation in gastric cancer: long-term outcomes and prognostic factors from a single institution.
    Bruixola G; Segura Á; Díaz-Beveridge R; Caballero J; Bennis MH; Palomar L; Giménez A; Mingol F; García-Mora C; Aparicio J
    Tumori; 2015; 101(5):517-23. PubMed ID: 26045120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of patients with lymph node metastasis from gastric cancer who may benefit from adjuvant chemoradiotherapy after D2 dissection--do N3 patients benefit from additional radiation?
    Fan M; Li G; Shen L; Zhang H; Liang L; Zhang Z
    Br J Radiol; 2016; 89(1059):20150758. PubMed ID: 26728420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
    Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Concurrent Chemoradiotherapy (CRT) plus Docetaxel-Cisplatin-Fluorouracil (DCF) versus CRT plus Fluorouracil-Folinic Acid (FUFA) in Stage III Gastric Cancer.
    Alkan A; Mızrak D; Yaşar A; Karcı E; Köksoy EB; Ürün M; Özyurt N; Kuştaş AA; Kütük T; Ürün Y; Şenler FÇ; Akyürek S; Utkan G; Demirkazık A; Gökçe ŞÇ; Akbulut H
    J Cancer Res Ther; 2024 Apr; 20(3):913-917. PubMed ID: 39023597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage.
    Shin K; Park SJ; Lee J; Park CH; Song KY; Lee HH; Seo HS; Jung YJ; Park JM; Lee SH; Roh SY; Kim IH
    BMC Cancer; 2019 Dec; 19(1):1232. PubMed ID: 31852475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemoradiation versus chemotherapy for stage III gastric cancer after surgery with curative intent.
    Turanli S; Atalay C; Berberoglu U; Gulben K
    J Cancer Res Ther; 2015; 11(2):369-74. PubMed ID: 26148602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
    Dikken JL; Jansen EP; Cats A; Bakker B; Hartgrink HH; Kranenbarg EM; Boot H; Putter H; Peeters KC; van de Velde CJ; Verheij M
    J Clin Oncol; 2010 May; 28(14):2430-6. PubMed ID: 20368551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age as a modifier of the effects of chemoradiotherapy with infusional 5-fluorouracil after D2 dissection in gastric cancer.
    Wu HC; Lin WL; Lin CL; Lin CY; Chen SW; Chen YX; Chen CH; Lee SW; Chen SH; Tsao CJ; Huang WT; Guo HR
    Aging (Albany NY); 2021 Jul; 13(13):17337-17348. PubMed ID: 34226296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.
    Datta J; McMillan MT; Ecker BL; Karakousis GC; Mamtani R; Plastaras JP; Giantonio BJ; Drebin JA; Dempsey DT; Fraker DL; Roses RE
    Ann Surg; 2016 Feb; 263(2):298-305. PubMed ID: 26135687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Efficacy of Adjuvant FOLFOX6 for Patients With Gastric Cancer after D2 Lymphadenectomy: A Propensity Score-matched Analysis.
    Wang ZX; Yang XL; He MM; Wang F; Zhang DS; Li YH; Zhou ZW; Zhan YQ; Xu RH
    Medicine (Baltimore); 2016 Apr; 95(16):e3214. PubMed ID: 27100411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADJUVANT CHEMORADIOTHERAPY AFTER SUBTOTAL OR TOTAL GASTRECTOMY AND D2 LIMPHADENECTOMY INCREASES SURVIVAL IN ADVANCED GASTRIC CANCER?
    Andreollo NA; Drizlionoks E; Tercioti-Junior V; Coelho-Neto JS; Ferrer JAP; Carvalheira JBC; Lopes LR
    Arq Bras Cir Dig; 2019; 32(4):e1464. PubMed ID: 31859917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic analysis of patients with operable gastric cancer and tolerability to adjuvant radio-chemo-therapy.
    Kucukoner M; Arpaci E; Isikdogan A; Bilici M; Uncu D; Cetin B; Dane F; Inanc M; Ekinci AS; Inal A; Cayir K; Yetisyigit T; Ozdemir N; Kaplan MA; Aksoy S; Alkıs N; Tekin SB; Eroglu C; Turhal S; Buyukberber S
    Neoplasma; 2013; 60(1):19-25. PubMed ID: 23067212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.